» Articles » PMID: 10602114

Variation in Microdeletions of the Cyclic AMP-responsive Element-binding Protein Gene at Chromosome Band 16p13.3 in the Rubinstein-Taybi Syndrome

Overview
Journal Am J Med Genet
Specialty Genetics
Date 1999 Dec 22
PMID 10602114
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Most reported microdeletions of the CREB-binding protein (CBP) gene in the Rubinstein-Taybi syndrome (RTS) were detected by fluorescence in situ hybridization (FISH) with a single cosmid probe specific to the 3' region of the gene. In order to test the hypothesis that the rate of microdeletion-positive cases would be greater if the entire gene was evaluated, we performed FISH on 66 patients with an established diagnosis of RTS, using a panel of five cosmids that span the CBP gene. Five of 66 patients had deletions by FISH (9%), consistent with those rates reported in various series that ranged between 3-25%. Among our cases, different deletions were observed; one was deleted for the 5' but not the 3' region of the CBP gene (case 055). Other deletions included a total CBP deletion extending from the 5' through the 3' region (case 017), a deletion of all but the 5' region (cases 006 and 060), and an interstitial deletion in the 3' region (case 028). Fine breakpoint mapping with additional cosmid and yeast artificial chromosome (YAC) constructs was performed on these patients. The findings of a partial 5' deletion and of interstitial deletions of the CBP gene add to the known spectrum of mutations of this gene in RTS and demonstrate the need for evaluation of the entire CBP gene region for deletions rather than only the 3' region in RTS patients. These results further suggest that the true rate of microdeletion across the CBP gene detectable by FISH has yet to be established firmly. No phenotypic differences between partial deletion, complete deletion, and nondeletion patients were observed, supporting a haploinsufficiency model for RSTS.

Citing Articles

Role of the ADCY9 gene in cardiac abnormalities of the Rubinstein-Taybi syndrome.

Wu Y, Xia Y, Li P, Qu H, Liu Y, Yang Y Orphanet J Rare Dis. 2020; 15(1):101.

PMID: 32321550 PMC: 7178576. DOI: 10.1186/s13023-020-01378-9.


Culture as a variable in neuroscience and clinical neuropsychology: A comprehensive review.

Wajman J, Bertolucci P, Mansur L, Gauthier S Dement Neuropsychol. 2017; 9(3):203-218.

PMID: 29213964 PMC: 5619361. DOI: 10.1590/1980-57642015DN93000002.


The emerging field of epigenetics in neurodegeneration and neuroprotection.

Hwang J, Aromolaran K, Zukin R Nat Rev Neurosci. 2017; 18(6):347-361.

PMID: 28515491 PMC: 6380351. DOI: 10.1038/nrn.2017.46.


Characterization of 14 novel deletions underlying Rubinstein-Taybi syndrome: an update of the CREBBP deletion repertoire.

Rusconi D, Negri G, Colapietro P, Picinelli C, Milani D, Spena S Hum Genet. 2015; 134(6):613-26.

PMID: 25805166 DOI: 10.1007/s00439-015-1542-9.


Whole exome sequencing for a patient with Rubinstein-Taybi syndrome reveals de novo variants besides an overt CREBBP mutation.

Yoo H, Kim K, Kim I, Rho S, Park J, Lee K Int J Mol Sci. 2015; 16(3):5697-713.

PMID: 25768348 PMC: 4394500. DOI: 10.3390/ijms16035697.